Professor Peter Brocklehurst MBChB, MSc, FRCOG, FFPH, FMedSci

Professor Peter Brocklehurst

Institute of Applied Health Research
Director, Birmingham Clinical Trials Unit (BCTU)

Contact details

Address
Birmingham Clinical Trials Unit
Institute of Applied Health Research
Room 106, Public Health Building
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Peter Brocklehurst is Professor of Women’s Health and Director of the Birmingham Clinical Trials Unit, in the Institute of Applied Health Research.

Peter trained as an Obstetrician and Gynaecologist before moving into academia to train as a perinatal epidemiologist.  He is a consultant in public health and his major research focus has been on randomised controlled trials in pregnancy and the newborn period, as well as observational studies which address topics of importance for clinical practice and policy, such as the safety of different planned places of birth e.g. at home, midwifery units or in hospital.

He has published widely in scientific journals and his work has been funded with grants from the National Institute of Health Research, Medical Research Council, Wellcome Trust and a variety of other funding bodies

Peter chairs the NIHR Health Technology Assessment Programme Panel in Maternal, Neonatal and Child health. He also sits on the NIHR Technology Assessment Programme Prioritisation Group. He chairs the MRC/NIHR Methodology Research Programme Research Panel. He is an NIHR Senior Investigator and Fellow of the Academy of Medical Sciences.

Qualifications

  • FMedSci, Academy of Medical Sciences 2015
  • FFPH, Faculty of Public Health, 2007
  • FRCOG, Royal College of Obstetricians & Gynaecologists, 2004
  • MSc Epidemiology, London School of Hygiene and Tropical Medicine, 1994
  • MRCOG, Royal College of Obstetricians & Gynaecologists, 1991
  • MBChB, University of Dundee, 1985

Biography

Peter qualified in medicine from the University of Dundee in 1985. He undertook house jobs in Glasgow and Manchester before moving to London to start training in Obstetrics and Gynaecology. As part of his obstetrics and gynaecology training, he undertook a period of research as a lecturer at the Middlesex Hospital undertaking a randomised controlled trial of aciclovir prophylaxis for pregnant women with frequently recurring genital herpes infection. After returning to clinical obstetrics and gynaecology at University College Hospital London, Peter decided to undertake formal training in epidemiology at the London School of Hygiene and Tropical Medicine where he graduated 1994.

Peter then joined the National Perinatal Epidemiology Unit at the University of Oxford as a research fellow in perinatal trials. Peter remained at the National Perinatal Epidemiology Unit for 17 years, becoming Director in 1996.

Peter left Oxford to become Director of the Institute for Women’s Health at University College London in 2011. As Director, he oversaw a large programme of research from basic science through to health policy research across the breath of women’s health and neonatology, as well as a full educational programme from undergraduate medical student teaching, two successful Masters courses in women’s health, as well as a vibrant postgraduate research training programme.

Peter came to the University of Birmingham in July 2016 as Professor of Women’s Health and Director of the Birmingham Clinical Trials Unit.

Postgraduate supervision

Peter is interested in supervising doctoral research students in the following areas:

  • Methodology of randomised controlled trials.
  • Exploring the mechanisms by which mother to child transmission of the gut microbiome influences later health outcomes.
  • Exploring the use of routine data in randomised controlled trial design, conduct, and outcome evaluation.

Other activities

  • Chair, UKCRC Regulatory and Governance Forum 2010-
  • Member Health Research Agency Collaboration and Development Steering Group 2012-
  • Chair of MRC Methodology Research Programme panel 2014-
  • Wellbeing of Women Trustee, 2014 -

Publications

Selected recent publications

Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M; on behalf of UKOSS. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ. 2011;342:d3214

Papo JK, Bauni EK, Sanders EJ, Brocklehurst P, Jaffe HW. Exploring the condom gap: is supply or demand the limiting factor - condom access and use in an urban and a rural setting in Kilifi district, Kenya. AIDS. 2011 Jan 14;25:247-55.

Birthplace in England Collaborative Group. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study. BMJ 2011;343:d7400

Kayem G , Kurinczuk J, Lewis G , Golightly S , Brocklehurst P , Knight, M. Risk factors for progression from severe maternal morbidity to death: A national cohort study. 2011 PLoS ONE 6(12): e29077. oi:10.1371/journal.pone.0029077

INIS Collaborative Group, Brocklehurst P, Farrell B, King A, Juszczak E, Darlow B, Haque K, Salt A, Stenson B, Tarnow-Mordi W. Treatment of Neonatal Sepsis with Intravenous Immune Globulin. N Engl J Med. 2011;365(13), 1201-1211.

Nuwagaba-Biribonwoha H, Mayon-White RT, Okong P, Brocklehurst P, Carpenter LM. The Impact of HIV on Maternal Morbidity in the Pre-HAART Era in Uganda. J Pregnancy 2012, 508657- doi:10.1155/2012/508657.

Schroeder E, Petrou S, Patel N, Hollowell J, Puddicombe D, Redshaw M, Brocklehurst P. Cost effectiveness of alternative planned places of birth in woman at low risk of complications: evidence from the Birthplace in England national prospective cohort study. BMJ 344:e2292 2012.

Leaf A, Dorling J, Kempley S, McCormick K, Mannix P, Linsell L, Juszczak E, Brocklehurst  P. Early or Delayed Enteral Feeding for Preterm Growth-Restricted Infants: A Randomized Trial. Pediatrics , 2012: 129; pp. e1260 -e1268. doi: 10.1542/peds.2011-2379.

Castanon A, Brocklehurst P, Evans H, Peebles D, Singh N, Walker P, Patnick J, Sasieni P, for the PaCT Study Group. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ 2012;345:e5174.

Marlow N, Morris T, Brocklehurst P, Carr R, Cowan FM, Patel N, Petrou S, Redshaw ME, Modi N, Dore C. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: Outcomes at 2 years. Arch Dis Child Fetal Neonatal Ed 98(1), F46-F53 doi:10.1136/fetalneonatal-2011-301470.

The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups.  Oxygen Saturation and Outcomes in Preterm Infants. N Engl J Med 2013; 368:2094-2104. May 30, 2013. DOI: 10.1056/NEJMoa1302298.

The CORONIS Collaborative Group. Caesarean section surgical techniques (CORONIS): a fractional, factorial, unmasked, randomised controlled trial. The Lancet 2013;382;234-248.

Castanon A, Landy R, Brocklehurst P, Evans H, Peebles  D, Singh N, Walker P, Patnick J, Sasieni P. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study BMJ 2014; 349:g6223.

Azzopardi, D, Strohm, B, Marlow, N, Brocklehurst, P, Deierl, A, Eddama, O, Goodwin, J, Halliday, HL, Juszczak, E, Kapellou, O, Levene, M, Linsell, L, Omar, O, Thoresen, M, Tusor, N, Whitelaw, A, Edwards, D. for TOBY Study Group. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med 2014, 371 (2), 140-149. doi:10.1056/NEJMoa1315788

Nair M, Kurinczuk JJ, Knight M, Brocklehurst P, Lewis G, Sellers S. Factors associated with maternal death from direct pregnancy complications: A UK national case-control study. BJOG: An International Journal of Obstetrics and Gynaecology, 2016; 122 (5), 653-662. doi:10.1111/1471-0528.13279.

Tarnow-Mordi, W., Stenson, B., Kirby, A., Juszczak, E., Donoghoe, M., Deshpande, S., Brocklehurst, P. Outcomes of two trials of oxygen-saturation targets in preterm infants. New England Journal of Medicine, 2016; 374 (8), 749-760. doi:10.1056/NEJMoa1514212

The CORONIS Collaborative Group. Caesarean section surgical techniques: 3 year follow-up of the CORONIS fractional factorial, unmasked, randomised, controlled trial. The Lancet 2016;388:62-72